Amylyx Reports Positive Safety Data for AMX0114 in First-in-Human ALS Trial
核心洞察
Amylyx Pharmaceuticals presented early safety and tolerability data from the Phase I LUMINA trial of AMX0114, an antisense oligonucleotide targeting calpain-2 (搜索) for ALS (搜索) treatment.
The first cohort of 12 participants showed AMX0114 was generally well-tolerated with no treatment-related serious adverse events reported.
Based on these positive safety results, Amylyx plans to begin enrolling the second cohort in Canada in December and in the US in January 2026.
Amylyx Pharmaceuticals has reported encouraging early safety and tolerability data from its Phase I LUMINA trial of AMX0114, an investigational antisense oligonucleotide targeting calpain-2 (搜索) for the treatment of amyotrophic lateral sclerosis (搜索) (ALS (搜索)). The data was presented at the 36th International Symposium on ALS/MND held from December 5-7, 2025, in San Diego, California.
Positive Safety Profile Enables Trial Progression
In the first cohort of the LUMINA trial, which included 12 participants, AMX0114 was generally well-tolerated with no treatment-related serious adverse events (SAEs) reported. Importantly, no dose-limiting toxicities were observed, representing crucial early milestones for this first-in-human study.
"We are pleased that to date no drug-related SAEs or dose-limiting toxicities were observed, which represent important early steps in this study," said Camille L. Bedrosian, MD, Chief Medical Officer at Amylyx.
Based on these positive safety results, Amylyx expects to begin enrolling the second cohort of participants in Canada later in December and in the US in January 2026.
Novel Mechanism Targeting Axonal Degeneration
AMX0114 is designed to inhibit calpain-2 (搜索), a calcium-activated protease identified as one of the fundamental drivers of axonal degeneration and consequent disease progression in ALS (搜索). The drug has received FDA Fast Track designation for the potential treatment of ALS.
Preclinical studies have demonstrated that treatment with AMX0114 resulted in potent, dose-dependent, and durable reduction in calpain-2 (搜索) protein levels, translating to improved neuronal survival and reductions in extracellular neurofilament light chain (NfL) levels across multiple disease models and paradigms of neuronal injury.
LUMINA Trial Design and Biomarker Assessment
The LUMINA trial (NCT06665165) is a multinational, randomized, double-blind, placebo-controlled, multiple ascending dose clinical trial evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of AMX0114 in people living with ALS (搜索). The study is anticipated to enroll approximately 48 adult participants across sites in Canada and the United States.
Participants are randomized 3:1 to receive AMX0114 or placebo by intrathecal administration once every four weeks for a total of up to 4 doses. The trial is assessing both novel and broadly researched ALS (搜索) biomarkers, including change from baseline in neurofilament light chain (NfL) levels and calpain-2 (搜索) levels.
Amylyx expects biomarker data from the first cohort of LUMINA participants in the first half of 2026, which will provide crucial insights into target engagement and potential therapeutic effects.
Clinical Significance for ALS Community
"LUMINA is a first-in-human study, and we are encouraged by these data as we continue to advance AMX0114 as a potential treatment for this rapidly progressive disease with high unmet need," said Sabrina Paganoni, MD, PhD, principal investigator of the LUMINA trial and investigator at the Sean M. Healey & AMG Center for ALS (搜索) at Mass General Brigham.
Dr. Paganoni emphasized the urgency of the research, noting that "the safety and tolerability analysis allows LUMINA to proceed with its next cohort of participants, which is critical given that this community has no time to wait."
ALS (搜索) is a relentlessly progressive and fatal neurodegenerative disorder caused by motor neuron death in the brain and spinal cord. Motor neuron loss leads to deteriorating muscle function, the inability to move and speak, respiratory paralysis, and eventually death. More than 90% of people with ALS have sporadic disease, showing no clear family history.